Clinical Trials Directory

Trials / Completed

CompletedNCT04214808

To Evaluate the Pharmacokinetics and Safety of AD-208

A Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of AD-208

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Addpharma Inc. · Industry
Sex
Male
Age
19 Years – 50 Years
Healthy volunteers
Accepted

Summary

To evaluate pharmacokinetics and safety of AD-208.

Detailed description

The purpose is that pharmacokinetics and safety of AD-208 in healthy adult male volunteers are evaluated as compared to Avodart Soft Capsule 0.5mg.

Conditions

Interventions

TypeNameDescription
DRUGAD-208Dutasteride 0.2mg
DRUGAvodart Soft Capsule 0.5mgDutasteride 0.5mg

Timeline

Start date
2020-01-03
Primary completion
2020-02-04
Completion
2020-05-04
First posted
2020-01-02
Last updated
2020-12-02

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT04214808. Inclusion in this directory is not an endorsement.